Eco-evolutionary dynamics of adapting pathogens and host immunity.

Publication date: Dec 27, 2024

As pathogens spread in a population of hosts, immunity is built up, and the pool of susceptible individuals are depleted. This generates selective pressure, to which many human RNA viruses, such as influenza virus or SARS-CoV-2, respond with rapid antigenic evolution and frequent emergence of immune evasive variants. However, the host’s immune systems adapt, and older immune responses wane, such that escape variants only enjoy a growth advantage for a limited time. If variant growth dynamics and reshaping of host-immunity operate on comparable time scales, viral adaptation is determined by eco-evolutionary interactions that are not captured by models of rapid evolution in a fixed environment. Here, we use a Susceptible/Infected model to describe the interaction between an evolving viral population in a dynamic but immunologically diverse host population. We show that depending on strain cross-immunity, heterogeneity of the host population, and durability of immune responses, escape variants initially grow exponentially, but lose their growth advantage before reaching high frequencies. Their subsequent dynamics follows an anomalous random walk determined by future escape variants and results in variant trajectories that are unpredictable. This model can explain the apparent contradiction between the clearly adaptive nature of antigenic evolution and the quasi-neutral dynamics of high-frequency variants observed for influenza viruses.

Open Access PDF

Concepts Keywords
Host Biological Evolution
Immunologically computational biology
Influenza coronavirus
Pool COVID-19
Rapid cross-immunity
Evolution, Molecular
evolutionary biology
evolutionary prediction
Host-Pathogen Interactions
Humans
Immune Evasion
influenza virus
Influenza, Human
Orthomyxoviridae
SARS-CoV-2
systems biology
viruses

Semantics

Type Source Name
disease IDO host
disease MESH influenza
disease IDO process
disease IDO pathogen
drug DRUGBANK Ilex paraguariensis leaf
disease MESH infections
disease IDO infection
disease IDO history
disease IDO susceptibility
disease IDO geographical region
disease IDO infectivity
drug DRUGBANK Naproxen
drug DRUGBANK Chlordiazepoxide
disease MESH mutation frequency
drug DRUGBANK Aspartame
drug DRUGBANK Coenzyme M
disease MESH Swine Influenza
drug DRUGBANK Isoxaflutole
disease MESH virus infection
pathway KEGG Influenza A
disease IDO cell
disease IDO susceptible population
drug DRUGBANK Spinosad
drug DRUGBANK Potassium
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)